tiprankstipranks
The Fly

Verve Therapeutics sees cash runway into mid-2027

Verve Therapeutics sees cash runway into mid-2027

With Verve’s existing cash, cash equivalents and marketable securities, including the milestone payment to be received from Lilly under the Lp(a) program, Verve expects its capital position to be sufficient to fund its operations into mid-2027.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com